Invivyd is a biopharmaceutical company focused on the discovery, development and commercialization of differentiated products for the prevention and/or treatment of viral infectious disease. Co. is obtaining regulatory authorization or approval for its lead product candidate, VYD222, for the prevention and/or treatment of SARS-CoV-2 (COVID-19). VYD222 is an engineered version of adintrevimab, Co.'s investigational monoclonal antibody. Co. is developing a pipeline of product candidates which could be used in prevention or treatment of serious viral diseases, starting with COVID-19 and expanding into influenza and other high-need indications. The IVVD average annual return since 2021 is shown above.
The Average Annual Return on the IVVD average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether IVVD average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the IVVD average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|